Alright, listen up degenerates. If you’ve been sleeping on ImmunityBio ($IBRX), now’s the time to wake the fuck up. This isn’t your average pump-and-dump biotech—these guys just got FDA approval for ANKTIVA, an absolute game-changer in the fight against bladder cancer. Translation? Real revenue incoming.
The stock is chilling at around $3.41, which is criminally undervalued considering they’re sitting on a multi-billion-dollar TAM (total addressable market). Oh, and they’ve got marketing applications pending in the UK and EU—when those approvals hit, expect some SERIOUS price action.
Yeah, yeah, I know the bears will whine about their losses, but let’s be real—biotechs burn cash before they print it. We’re at the inflection point. The company already quadrupled its revenue last quarter, and that’s before the real money even starts rolling in.
$IBRX is on the launchpad, and the rocket boosters are warming up. You know the drill—buy, hold, and watch the boomers panic-buy at $20+.
Not financial advice, just a smooth-brained ape connecting dots.
Positions: 10,000 shares and 4c 3/21